首页> 外文期刊>The Tokai Journal of Experimental and Clinical Medicine >Platelet Activation in Patients with Alcoholic Liver Disease
【24h】

Platelet Activation in Patients with Alcoholic Liver Disease

机译:酒精性肝病患者的血小板活化

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To elucidate the mechanisms of thrombocytopenia in alcoholic liver diseases, we investigated activation status of platelets in patients with alcoholic fatty liver (Al-FL), alcoholic liver cirrhosis (Al-LC) or hepatitis-C liver cirrhosis C (C-LC). Methods: Platelet activation was evaluated by flow cytometry using monoclonal antibodies against P-selectin (CD62P) and the fibrinogen receptor (PAC-1), both specific for platelet activation, and anti-CD61 antibody for the presence of microparticles (PMP) in seven patients with Al-FL, thirteen patients with Al-LC and, as a non-alcoholic liver disease control, nine patients with C-LC. As a normal control, seventeen healthy subjects without liver dysfunction were also evaluated. Results: Compared with the healthy controls, the platelet count was significantly decreased in patients with alcoholic liver diseases or C-LC. Ten days after discontinuation of alcohol intake, the platelet count was significantly higher in both the Al-FL and Al-LC groups than that measured on admission. There was an inverse correlation between the platelet count and PMP, a marker of platelet activation. The Al-FL, Al-LC and C-LC groups showed significantly higher percentages of platelets positive for CD62P than the healthy controls. The PAC-1 positivity was increased only in the C-LC group. PMP were significantly increased in the Al-FL, Al-LC and C-LC groups compared to that in the healthy group. In the Al-LC group, PMP were significantly decreased 10 days after discontinuation of alcohol intake from that measured on admission. Conclusion: Patients with alcoholic liver diseases have increased platelet activation, which may contribute to the occurrence of thrombocytopenia. The formation of PMP might be one of the important factors of thrombocytopenia in alcoholic liver diseases.
机译:目的:为阐明酒精性肝病中血小板减少症的机制,我们调查了酒精性脂肪肝(Al-FL),酒精性肝硬化(Al-LC)或丙型肝炎C型肝硬化(C-LC)患者的血小板活化状态)。方法:通过流式细胞术评估血小板活化,使用针对血小板活化的特异性抗P-选择蛋白(CD62P)和纤维蛋白原受体(PAC-1)的单克隆抗体,以及七个中存在微粒(PMP)的抗CD61抗体Al-FL患者,13位Al-LC患者和9位C-LC患者(作为非酒精性肝病对照)。作为正常对照,还评估了十七名没有肝功能障碍的健康受试者。结果:与健康对照组相比,酒精性肝病或C-LC患者的血小板计数显着降低。停止饮酒十天后,Al-FL和Al-LC组的血小板计数均显着高于入院时的血小板计数。血小板计数与血小板活化指标PMP呈负相关。 Al-FL,Al-LC和C-LC组的CD62P阳性血小板百分比明显高于健康对照组。仅在C-LC组中PAC-1阳性增加。与健康组相比,Al-FL,Al-LC和C-LC组的PMP显着增加。在Al-LC组中,停止摄入酒精后10天的PMP较入院时显着降低。结论:酒精性肝病患者血小板活化增加,可能与血小板减少症的发生有关。 PMP的形成可能是酒精性肝病血小板减少的重要因素之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号